Tiziana Life Sciences Ltd

NASDAQ
TLSA
Stock
Yield per half year: +47.61%
Dividend yield: 0%
Sector: Healthcare

Share chart Tiziana Life Sciences Ltd

Extended chart Simple chart
Financial Markets by TradingView

About Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

more details
It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2000-03-24
ISIN BMG889121031
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Цена ао 1.58
Change price per day: -5.03% (1.43)
Change price per week: -4.37% (1.42)
Change price per month: +3.66% (1.31)
Change price per 3 month: +38.57% (0.98)
Change price per half year: +47.61% (0.92)
Change price per year: +47.77% (0.919)
Change price per 3 year: +92.62% (0.705)
Change price per 5 year: -51.41% (2.7949)
Change price per year to date: +96.81% (0.69)
All parameters

Grade

Underestimation
Title Value Grade
P/S 0 0
P/BV 2.91 6
P/E 0 0
EV/EBITDA -2.55 0
Total: 3.25
Efficiency
Title Value Grade
ROA, % -145.2 0
ROE, % -319.56 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA -0.0161 10
Total: 9.6
Growth impulse
Title Value Grade
Yield Revenue, % -97.64 0
Yield Ebitda, % 29.82 4
Yield EPS, % 1356.45 10
Total: 5.4
More

Main owners

Institutions Volume Share, %
Geode Capital Management, LLC 211 167 0.21
HSBC Holdings PLC 164 226 0.16
Morgan Stanley 124 131 0.12
Ausdal Financial Partners, Inc. 55 700 0.05
Zhang Financial LLC 52 060 0.05
Ewa, LLC 43 476 0.04
UBS Group AG 28 559 0.03
Bank of America Corporation 27 011 0.03
Barclays PLC 17 500 0.02
Cubist Systematic Strategies, LLC 12 099 0.01

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Gabriele Marco Antonio Cerrone M.B.A. Founder, Executive Chairman & Interim CEO 817k 1972 (53 years)
Ms. Keeren Shah Chief Financial Officer 1976 (49 years)
Dr. William A. Clementi Ph.D., Pharm.D. Chief Development Officer
Dr. Napoleone Ferrara M.D. Member of Scientific Advisory Board 1957 (68 years)

About company

Address: United Kingdom, London WS XJ, 14/15 Conduit Street - Open in google maps, Open in yandex maps
Website: https://www.tizianalifesciences.com